AMGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 6.9% compared to Amgen's net margin of 50.24%. Amgen's return on equity of 66.87% beat Johnson & Johnson's return on equity of 30.18%.

Amgen has a consensus price target of $314.62, signalling upside risk potential of 12.03%. On the other hand Johnson & Johnson has an analysts' consensus of $169.84 which suggests that it could grow by 9.87%. Given that Amgen has higher upside potential than Johnson & Johnson, analysts believe Amgen is more attractive than Johnson & Johnson.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.25%. Johnson & Johnson offers a yield of 3.21% to investors and pays a quarterly dividend of $1.24 per share. Amgen pays 118.14% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $9.1B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Amgen's net income of $627M is lower than Johnson & Johnson's net income of $11B. Notably, Amgen's price-to-earnings ratio is 37.20x while Johnson & Johnson's PE ratio is 17.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.54x versus 4.20x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 6.9% compared to Amgen's net margin of 32.59%. Amgen's return on equity of 66.87% beat Eli Lilly and's return on equity of 80.24%.

Amgen has a consensus price target of $314.62, signalling upside risk potential of 12.03%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 14.03%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.25%. Eli Lilly and offers a yield of 0.61% to investors and pays a quarterly dividend of $1.50 per share. Amgen pays 118.14% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $9.1B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Amgen's net income of $627M is lower than Eli Lilly and's net income of $4.4B. Notably, Amgen's price-to-earnings ratio is 37.20x while Eli Lilly and's PE ratio is 75.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.54x versus 17.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 6.9% compared to Amgen's net margin of -117.16%. Amgen's return on equity of 66.87% beat Moderna's return on equity of -29.09%.

Amgen has a consensus price target of $314.62, signalling upside risk potential of 12.03%. On the other hand Moderna has an analysts' consensus of $49.96 which suggests that it could grow by 83.55%. Given that Moderna has higher upside potential than Amgen, analysts believe Moderna is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.25%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Moderna quarterly revenues of $956M. Amgen's net income of $627M is higher than Moderna's net income of -$1.1B. Notably, Amgen's price-to-earnings ratio is 37.20x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.54x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 6.9% compared to Amgen's net margin of 24.22%. Amgen's return on equity of 66.87% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Amgen has a consensus price target of $314.62, signalling upside risk potential of 12.03%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $850.21 which suggests that it could grow by 41.08%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.25%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Amgen pays 118.14% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Amgen's net income of $627M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Amgen's price-to-earnings ratio is 37.20x while Regeneron Pharmaceuticals's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.54x versus 4.88x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.